Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AHOD0831||COG||A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|NRG-CC008||NRG||A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]||Cancer Prevention and Control CIRB||Available to Open|
|10015||ETCTN||A Non-Randomized; Open-Label; Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma||Adult CIRB - Early Phase Emphasis||Available to Open|
|PBTC-053||PBTC||A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma||Pediatric CIRB||Available to Open|
|10371||ETCTN||A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response||Adult CIRB - Early Phase Emphasis||Available to Open|
|ADVL06B1||COG||A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer: A Group-Wide Non-Therapeutic Study||Pediatric CIRB||Completed|
|10401||ETCTN||A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|10066||ETCTN||A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10076||ETCTN||A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma.||Adult CIRB - Early Phase Emphasis||Available to Open|
|9844||ETCTN||A Phase 1 Study Evaluating Safety; Tolerability; and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|